Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Neuroendocrine tumors: a critical appraisal of management strategies.

Vinik AI, Anthony L, Boudreaux JP, Go VL, O'Dorisio TM, Ruszniewski P, Woltering EA.

Pancreas. 2010 Aug;39(6):801-18. doi: 10.1097/MPA.0b013e3181ea5839.

PMID:
20664478
[PubMed - indexed for MEDLINE]
2.

Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.

Janson ET, Oberg K.

Cancer Chemother Biol Response Modif. 2003;21:535-46. Review. No abstract available.

PMID:
15338762
[PubMed - indexed for MEDLINE]
3.

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.

Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B.

Ann Oncol. 2004 Jun;15(6):966-73. Review.

PMID:
15151956
[PubMed - indexed for MEDLINE]
Free Article
4.

Established clinical use of octreotide and lanreotide in oncology.

Oberg K.

Chemotherapy. 2001;47 Suppl 2:40-53. Review.

PMID:
11275701
[PubMed - indexed for MEDLINE]
5.

Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence?

Zedenius J.

Acta Oncol. 2008;47(1):3-4. No abstract available.

PMID:
17891671
[PubMed - indexed for MEDLINE]
6.

[Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].

Sperlongano P, De Falco M, Pisaniello D, Parmeggiani D, Parmeggiani U.

Minerva Endocrinol. 2001 Dec;26(4):293-5. Italian.

PMID:
11782719
[PubMed - indexed for MEDLINE]
7.

Role of Somatostatin Analogues in Oncology. European Neuroendocrine Tumor Network (ENET). February 24-27, 2000, Innsbruck, Austria. Proceedings.

[No authors listed]

Digestion. 2000;62 Suppl 1:1-108. No abstract available.

PMID:
11001649
[PubMed - indexed for MEDLINE]
8.

Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.

Gardner-Roehnelt NM.

Clin J Oncol Nurs. 2012 Feb;16(1):56-64. doi: 10.1188/12.CJON.56-64.

PMID:
22297008
[PubMed - indexed for MEDLINE]
9.

[Role of somatostatin analogs in the treatment of neuroendocrine tumours].

Cuccurullo V, Cascini GL, Rambaldi PF, Mansi L.

Minerva Endocrinol. 2001 Sep;26(3):135-43. Review. Italian.

PMID:
11753236
[PubMed - indexed for MEDLINE]
10.

The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.

Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.

Clin Endocrinol (Oxf). 1998 Mar;48(3):303-9.

PMID:
9578820
[PubMed - indexed for MEDLINE]
11.

[Medical treatment of digestive neuroendocrine tumours].

Panzuto F, Nasoni S, Delle Fave G.

Minerva Endocrinol. 2001 Sep;26(3):145-8. Review. Italian.

PMID:
11753237
[PubMed - indexed for MEDLINE]
12.

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.

Oberg K.

Expert Rev Anticancer Ther. 2009 May;9(5):557-66. doi: 10.1586/era.09.26. Review.

PMID:
19445573
[PubMed - indexed for MEDLINE]
13.

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.

Ann Oncol. 2000 Sep;11(9):1127-30.

PMID:
11061606
[PubMed - indexed for MEDLINE]
Free Article
14.

The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.

Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L.

Ann Oncol. 2001;12 Suppl 2:S105-9. Review.

PMID:
11762334
[PubMed - indexed for MEDLINE]
15.

[Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].

Hansen CP, Knigge U.

Ugeskr Laeger. 2008 Jun 9;170(24):2145-8. Danish.

PMID:
18565299
[PubMed - indexed for MEDLINE]
16.

Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors.

Pivonello R, Ferone D, Filippella M, Faggiano A, De Martino MC, Auriemma RS, Rota F, Lombardi G, Colao A.

J Endocrinol Invest. 2003;26(8 Suppl):82-8. Review. No abstract available.

PMID:
15233220
[PubMed - indexed for MEDLINE]
17.

Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.

Colao A, Faggiano A, Pivonello R.

Prog Brain Res. 2010;182:281-94. doi: 10.1016/S0079-6123(10)82012-6.

PMID:
20541670
[PubMed - indexed for MEDLINE]
18.

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

Oberg K.

Ann Oncol. 2001;12 Suppl 2:S111-4. Review.

PMID:
11762335
[PubMed - indexed for MEDLINE]
19.

Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?

Oberg KE.

J Clin Oncol. 2009 Oct 1;27(28):4635-6. doi: 10.1200/JCO.2009.23.6711. Epub 2009 Aug 24. No abstract available.

PMID:
19704053
[PubMed - indexed for MEDLINE]
Free Article
20.

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.

Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P.

Eur J Cancer. 2001 May;37(8):1014-9.

PMID:
11334727
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk